| Literature DB >> 33976247 |
Pierre Kantor1, Frédéric Matonti2,3, Fanny Varenne1, Vanessa Sentis1, Véronique Pagot-Mathis1, Pierre Fournié1,4, Vincent Soler5,6.
Abstract
Heads-up three-dimensional (3D) surgical visualization systems allow ophthalmic surgeons to replace surgical microscope eyepieces with high-resolution stereoscopic cameras transmitting an image to a screen. We investigated the effectiveness and safety of the heads-up NGENUITY 3D Visualization System in a retrospective evaluation of 241 consecutive vitreoretinal surgeries performed by the same surgeon using conventional microscopy (CM group) over a 1-year period versus the NGENUITY System (3D group) over a consecutive 1-year period. We included for study vitreoretinal surgeries for treatment of retinal detachment (RD) (98 surgeries), macular hole (MH) (48 surgeries), or epiretinal membrane (ERM) (95 surgeries). A total of 138 and 103 eyes were divided into 3D and CM groups, respectively. We found no differences in 3-month postoperative rates of recurrence of RD (10% versus 18%, p = 0.42), MH closure (82% versus 88%, p = 0.69), or decrease in central macular thickness of ERMs (134 ± 188 µm versus 115 ± 105 µm, p = 0.57) between the 3D and CM groups, respectively. Surgery durations and visual prognosis were also similar between both groups. We consolidate that the NGENUITY System is comparable in terms of visual and anatomical outcomes, giving it perspectives for integration into future robotized intervention.Entities:
Year: 2021 PMID: 33976247 PMCID: PMC8113355 DOI: 10.1038/s41598-021-88993-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Our operating room configuration with the heads-up NGENUITY 3D Visualization System. The microscope eyepieces were left in place for the conventional microscopy (CM) group and replaced by the three dimensional (3D) camera system for the 3D group with the NGENUITY v1.2.9 software version.
Figure 2Use of the heads-up NGENUITY 3D Visualization System with a patient in semi-sitting position in our center. Patients who can only be operated on in a semi-sitting position can be operated on by the surgeon standing.
Demographic data and ophthalmology history of patients included for study.
| 3D group | CM group | p value | |
|---|---|---|---|
| Number of patients, n | 131 | 96 | |
| Number of eyes, n (% total) | 138 (57%) | 103 (43%) | |
| Age in years, mean (± SD) | 65.3 (± 12.7) | 65.9 (± 12.8) | 0.69d |
| 0.17e | |||
| Male | 67 (49%) | 60 (58%) | |
| Female | 71 (51%) | 43 (42%) | |
| 0.9f. | |||
| Left | 80 (58%) | 58 (56%) | |
| Right | 58 (42%) | 45 (44%) | |
| 0.35f | |||
| Low myopiaa | 66 (48%) | 42 (41%) | |
| Low hyperopiab | 56 (41%) | 43 (42%) | |
| High myopiac | 16 (12%) | 18 (17%) | |
| 0.30e | |||
| Phakia | 86 (63%) | 57 (55%) | |
| Pseudophakia | 51 (36%) | 46 (45%) | |
| Aphakia | 1 (0.73%) | 0 (0%) | |
| 0.084f | |||
| No | 70 (50.72%) | 65 (63.14%) | |
| Yes | |||
| Anterior segment surgery | 5 (3.6%) | 6 (5.82%) | |
| RD | 16 (11.6%) | 11 (10.68%) | |
| OHT/Glaucoma | 10 (7.24%) | 6 (5.85%) | |
| Macular surgery | 12 (8.69%) | 3 (2.91%) | |
| Eye diseases (RVO, ARMD, ME) | 18 (13.04%) | 10 (9.71) | |
| Posterior uveitis | 9 (6.52) | 2 (1.94%) | |
| Retinopexy | 6 (4.34%) | 4 (3.88%) | |
| Non-perforating contusion | 2 (1.45%) | 2 (1.94%) |
3D group three-dimensional group, ARMD age-related macular degeneration, CM group conventional microscopy group, ME macular edema, OHT ocular hypertension, RD retinal detachment, RVO retinal vein occlusion, SD standard deviation.
aLow myopia: spherical equivalent of 0–5.5 D.
bLow hyperopia: spherical equivalent of 0–4.5 D.
cHigh myopia: spherical equivalent of < − 6 D or axial length > 26 mm.
dWelch’s t-test.
eFisher’s exact test.
f: Chi-squared test.
Indications for surgery and the surgical techniques performed in the three-dimensional (3D) and conventional microscopy (CM) patient groups.
| 3D group | CM group | p value | |
|---|---|---|---|
| 0.25a | |||
| RD | |||
| Vitrectomy | 56 (41%) | 35 (48%) | |
| Scleral buckling alone | 3 (2.2%) | 4 (3.9%) | |
| ERM | 49 (36%) | 46 (45%) | |
| MH | 30 (22%) | 18 (17%) | |
| 0.81b | |||
| No | 114 (83%) | 83 (81%) | |
| Yes | 24 (17%) | 20 (19%) | |
| 0.065a | |||
| 25-Gauge | 117 (85%) | 75 (73%) | |
| 27-Gauge | 17 (12%) | 24 (23%) | |
| Scleral buckling | 3 (2.9%) | 4 (4.9%) | |
| 0.36b | |||
| Outpatient | 112 (81%) | 89 (86%) | |
| Inpatient | 26 (19%) | 14 (14%) | |
| Retinopexy, n (% total RD) | 0.261a | ||
| Cryoapplication | 37 (63%) | 20 (51%) | |
| Endolaser | 18 (31%) | 14 (36%) | |
| Cryoapplication + endolaser | 2 (3.4%) | 0 (0%) | |
| Scleral buckling, n (% total RD) | 0.165a | ||
| No | 55 (93.2%) | 32 (82%) | |
| > 2 quadrants | 2 (1.7%) | 4 (10%) | |
| 2 quadrants | 1 (1.7%) | 3 (7.7%) | |
| 1 quadrant | 1 (1.7%) | 0 (0%) | |
| Internal tamponade agent, n (% total RD) | 0.720a | ||
| C2F6 | 45 (76%) | 30 (86%) | |
| Silicone oil 1000 | 4 (6.8%) | 4 (10%) | |
| Oxane HD | 3 (5.1%) | 1 (2.6%) | |
| SF6 | 2 (3.4%) | 0 (0%) | |
| C3F8 | 1 (1.7%) | 0 (0%) | |
| Silicone oil 5000 | 1 (1.7%) | 0 (0%) | |
| Flap , n (% total MH) | 0.061a | ||
| Yes | 17 (57%) | 8 (44%) | |
| No | 8 (27%) | 10 (56%) | |
| Free flap | 5 (17%) | 0 (0%) | |
| ILM peeling, n (% total MH) | 0.09a | ||
| Yes | 30 (100%) | 15 (78%) | |
| No | 0 (0%) | 3 (17%) | |
| Internal tamponade agent, n (% total MH) | 0.28b | ||
| SF6 | 26 (81%) | 18 (86%) | |
| C2F6 | 4 (13%) | 0 (0%) | |
| ILM peeling, n (% total ERM) | 1b | ||
| Yes | 37 (77%) | 35 (76%) | |
| No | 11 (23%) | 11 (24%) | |
ERM epiretinal membrane, ILM internal limiting membrane, MH macular hole, RD retinal detachment.
aFisher’s exact test.
bChi-squared test.
Initial anatomical characteristics of patients in the three-dimensional (3D) and conventional microscopy (CM) patient groups.
| 3D group | CM group | p value | |
|---|---|---|---|
| Total | 0.837 (± 0.741) | 0.713 (± 0.606) | 0.17a |
| RD | 1.19 (± 0.887) | 0.930 (± 0.564) | 0.143a |
| MH | 0.637 (± 0.312) | 0.832 (± 0.393) | 0.062a |
| ERM | 0.531 (± 0.530) | 0.487 (± 0.365) | 0.64a |
| Macular status, n (% total RD) | 0.58b | ||
| Detached | 32 (54%) | 20 (51%) | |
| Flat | 22 (37%) | 13 (33%) | |
| Pucker | 5 (8.5%) | 6 (15%) | |
| Lesion type, n (% total RD) | 0.23b | ||
| Tear | 45 (75%) | 27 (69%) | |
| Hole | 9 (15%) | 11 (28%) | |
| PVR | 3 (5%) | 0 (0%) | |
| Not visible | 3 (5%) | 1 (2.6%) | |
| Ear size in quadrant lengths, n (% total RD) | 1b | ||
| < 1 | 44 (91.7%) | 34 (91.9%) | |
| > 1 | 3 (6.1%) | 3 (8.1%) | |
| PVR, n (% total RD) | 0.56b | ||
| Grade A | 2 (3.4%) | 2 (5.1%) | |
| Grade B | 12 (20%) | 8 (21%) | |
| Grade C1 | 4 (6.8%) | 6 (15%) | |
| Grade > C1 | 3 (5.1%) | 3 (7.7%) | |
| No | 38 (66%) | 24 (51%) | |
| History of ipsilateral RD, n (% total RD) | 0.3c | ||
| Yes | 12 (20%) | 4 (10%) | |
| No | 47 (80%) | 35 (90%) | |
| Duration of evolution, n (% total RD) | 0.782c | ||
| 1–3 days | 11 (19%) | 6 (15%) | |
| 4–7 days | 16 (27%) | 9 (23%) | |
| ≥ 8 days | 22 (37%) | 18 (46%) | |
| Unknown | 10 (17%) | 6 (11%) | |
| CMT in µM, mean (± SD) | 423 (± 63.4) | 439 (± 78.8) | 0.48d |
| MH diameter in µM, mean (± SD) | 360 (± 137) | 384 (± 160) | 0.20a |
| Duration of evolution, n (% total MH) | 0.29b | ||
| 8 days–3 months | 12 (0%) | 10 (53%) | |
| 3–6 months | 8 (27%) | 1 (5.6%) | |
| 6 months–1 year | 4 (13%) | 2 (11%) | |
| Unknown | 5 (17%) | 6 (33%) | |
| Etiology, n (% total ERM) | 1b | ||
| Primary | 29 (61%) | 28 (61%) | |
| Secondary | 19 (39%) | 18 (39%) | |
| Initial macular thickness in µM, mean (± SD) | 510 (± 141) | 486 (± 92.3) | 0.33e |
BCVA best corrected visual acuity, CMT central macular thickness, ERM epiretinal membrane, LogMAR logarithm of the minimum angle of resolution, MH macular hole, PVR proliferative vitreoretinopathy, RD retinal detachment, SD standard deviation.
aStudent’s t-test.
bFisher’s exact test.
cChi-squared test.
dMann–Whitney U test.
eWelch’s t-test.
Anatomical outcomes according to disease subgroup in the three-dimensional (3D) and conventional microscopy (CM) patient groups.
| 3D group | CM group | p value | |
|---|---|---|---|
| Total | 0.494 (± 0.545) | 0.487 (± 0.539) | 0.096a |
| RD | 0.706 (± 0.750) | 0.516 (± 0.591) | 0.18a |
| ERM | 0.272 (± 0.200) | 0.379 (± 0.358) | 0.079a |
| MH | 0.458 (± 0.243) | 0.406 (± 0.337) | 0.31b |
| Total | 0.428 (± 0.531) | 0.388 (± 0.461) | 0.34a |
| RD | 0.576 (± 0.691) | 0.415 (± 0.508) | 0.23a |
| ERM | 0.241 (± 0.235) | 0.283 (± 0.294) | 0.49a |
| MH | 0.431 (± 0.425) | 0.443 (± 0.348) | 0.086b |
| Total | − 0.331 (± 0.640) | − 0.221 (± 0.461) | 0.15a |
| RD | − 0.471 (± 0.823) | − 0.249 (± 0.706) | 0.46a |
| ERM | − 0.268 (± 0.510) | − 0.115 (± 0.284) | 0.082a |
| MH | − 0.179 (± 0.345) | − 0.426 (± 0.369) | 0.048b |
| Total | − 0.371 (± 0.707) | − 0.347 (± 0.522) | 0.79a |
| RD | − 0.533 (± 0.721) | − 0.474 (± 0.716) | 0.90a |
| ERM | − 0.286 (± 0.452) | − 0.208 (± 0.335) | 0.38a |
| MH | − 0.199 (± 0.532) | − 0.398 (± 0.380) | 0.19b |
| 0.322c | |||
| Cataract | 21 (8.7%) | 14 (5.8%) | |
| RD | 7 (2.9%) | 8 (3.31%) | |
| Secondary ERM | 4 (1.65%) | 3 (1.25) | |
| Post-operative macular edema | 22 (9.1) | 19 (7.92) | |
| PCO | 1 (0.4%) | 5 (2.1%) | |
| Other | 8 (3.32%) | 2 (0.83%) | |
| None | 77 (32%) | 55 (22.8%) | |
| Homolateral recurrence, n (% total RD) | 0.42d | ||
| Not within 3-postoperative months | 53 (90%) | 32 (82%) | |
| Within 3-postoperative months | 6 (10%) | 7 (18%) | |
| 3-month postoperative closure, n (% total MH) | 0.69c | ||
| Yes | 23 (82%) | 16 (89%) | |
| No | 5 (18%) | 2 (11%) | |
| 3-month postoperative CMT in µM, mean (± SD) | 364 (± 77.6) | 379 (± 81.2) | 0.46a |
| 3-month postoperative CMT decrease in µM, mean (± SD) | − 154 (± 159) | − 115 (± 105) | 0.23a |
CMT central macular thickness, ERM epiretinal membrane, LogMAR logarithm of the minimum angle of resolution, MH macular hole, PCO posterior capsular opacification, RD retinal detachment, SD standard deviation.
aWelch’s t-test.
bMann–Whitney U test.
cFisher’s exact test.
dChi-squared test.
Surgery duration according to disease subgroup in the three-dimensional (3D) and conventional microscopy (CM) patient groups.
| Surgery duration in min, mean (± SD) | 3D group | CM group | p value |
|---|---|---|---|
| Total | 45.4 (± 20.1) | 46.0 (± 19.8) | 0.81a |
| RD | 47.9 (± 24.6) | 58.5 (± 4.24) | 0.037a |
| ERM | 38.5 (± 11.4) | 37.5 (± 12.2) | 0.68a |
| MH | 51.9 (± 18.6) | 40.8 (± 9.24) | 0.023a |
ERM epiretinal membrane, MH macular hole, RD retinal detachment, SD standard deviation.
aWelch’s t-test.